저용량 대 고용량 방사성요오드 치료

Abstract

Since 1946, radioiodine (I-131) therapy has been one of the standard treatments for differentiated thyroid cancer (DTC). Recently the occurrence of thyroid cancer was markedly increasing and most of them were limited disease. Several reports said that there is no significant difference of outcome between low and high dose radioiodine therapy in patients with low to intermediate risk category of thyroid cancer. In this review, current effectiveness and toxicity of radioiodine ablation will be compared between low and high dose radioiodine in patient with low to intermediate risk DTC.